Wire · opportunities
5 drugmakers chasing Merck and Moderna in the cancer vaccine race
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 September 2026 · Fusion42 review
Merck and Moderna achieved a significant milestone with their personalized mRNA-based cancer vaccine showing improved progression-free survival in melanoma patients, prompting other drugmakers to advance cancer vaccine development. The approach uses patient-specific tumor mutational signatures to prime the immune system, marking a breakthrough in therapeutic cancer vaccines.
This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 19 Aug 2026 and 14 Sep 2026.
◆ ◆ The Wire takeaway
Your best move in cancer treatment tech is pivoting to personalised immunotherapies using mRNA signatures. Investors are backing the shift from generic to patient-specific vaccines, so build partnerships with immunotherapy centres now.
◆ Coverage
9 sources · first reported 19 Aug 2026 · latest 14 Sep 2026
◆ Topics